Skip to Content

Join the 'Eculizumab' group to help and get support from people like you.

Eculizumab News

FDA Approves Soliris (eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (GMG)

Posted 26 Oct 2017 by Drugs.com

NEW HAVEN, Conn.--(BUSINESS WIRE) October 23, 2017 --Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive. In the Phase 3 REGAIN study and its ongoing open-label extension ...

Cancer Drugs' High Prices Not Justified by Cost of Development, Study Contends

Posted 12 Sep 2017 by Drugs.com

TUESDAY, Sept. 12, 2017 – Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs. But a new analysis, focused on 10 new cancer drugs, finds those costs may have been greatly exaggerated – and the return on investment for drug companies is lucrative indeed. The study found that the typical R&D process for a ...

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the ...

FDA Medwatch Alert: Soliris (Eculizumab) Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles

Posted 16 Dec 2013 by Drugs.com

ISSUE: Alexion Pharmaceuticals, Inc. is providing information regarding a previously communicated voluntary recall of two lots of Soliris (eculizumab) Concentrated Solution for Intravenous Infusion. As stated on Nov. 12, 2013, the two lots were found to contain visible particles. At that time, Alexion provided instructions to return any unused vials of Soliris from these two lots at the ...

Soliris (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Posted 25 Sep 2011 by Drugs.com

CHESHIRE, Conn.--(BUSINESS WIRE)--Sep 23, 2011 - Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) for the treatment of all pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). aHUS is an ultra-rare, life-threatening, genetic disease that progressively damages vital organs, leading to stroke, ...

Ask a Question

Further Information

Related Condition Support Groups

Myasthenia Gravis, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria

Related Drug Support Groups

Soliris

Eculizumab Patient Information at Drugs.com